Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy

Diabetes

Volumn 63, Issue 2, 2014, Pages 701-714

  Guzman, Johanna ^a   Jauregui, Alexandra N ^a   Merscher Gomez, Sandra ^a   Maiguel, Dony ^a   Muresan, Cristina ^a   Mitrofanova, Alla ^a   Diez Sampedro, Ana ^a   Szust, Joel ^a   Yoo, Tae Hyun ^a   Villarreal, Rodrigo ^a   Pedigo, Christopher ^a   Molano, R Damaris ^a   Johnson, Kevin ^a   Kahn, Barbara ^b   Hartleben, Bjoern ^c   Huber, Tobias B ^c   Saha, Jharna ^d   Burke Iii, George W ^a   Abel, E Dale ^e   Brosius, Frank C ^d   Fornoni, Alessia ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GENE DELETION; GLOMERULUS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY HYPERTROPHY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; SIGNAL TRANSDUCTION; WILD TYPE;

ALBUMINURIA; ANIMALS; CELL SIZE; DIABETIC NEPHROPATHIES; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION; GLOMERULAR FILTRATION BARRIER; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; LIPOPOLYSACCHARIDES; MICE; PODOCYTES;

EID: 84893075800     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0752     Document Type: Article

References (54)

1. Mogensen CE, Christensen NJ, Gundersen HJ. The acute effect of insulin on heart rate, blood pressure, plasma noradrenaline and urinary albumin excretion. The role of changes in blood glucose. Diabetologia 1980;18: 453-457
2. Ekstrand AV, Groop PH, Grönhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1998;13:3079-3083
3. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993;342:883-887
4. Groop L, Ekstrand A, Forsblom C, et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:642-647
5. Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006;55:1456-1462
6. Forsblom CM, Eriksson JG, Ekstrand AV, Teppo AM, Taskinen MR, Groop LC. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 1995;38: 363-369
7. Yip J, Mattock M, Sethi M, Morocutti A, Viberti G. Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria. Lancet 1993;341:369-370
8. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793-800
9. Musso C, Javor E, Cochran E, Balow JE, Gorden P. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol 2006;1:616-622
10. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007;17:428-437
11. Coward RJ, Welsh GI, Yang J, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005;54:3095-3102
12. Tejada T, Catanuto P, Ijaz A, et al. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 2008;73:1385-1393
13. Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010;12: 329-340
14. Fornoni A. Proteinuria, the podocyte, and insulin resistance. N Engl J Med 2010;363:2068-2069
15. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000;106:165-169
16. Kume S, Thomas MC, Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012;61:23-29
17. Eid AA, Ford BM, Block K, et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem 2010;285:37503-37512
18. Gödel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011;121: 2197-2209
19. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011;121:2181-2196
20. Moutzouris DA, Kitsiou PV, Talamagas AA, Drossopoulou GI, Kassimatis TI, Katsilambros NK. Chronic exposure of human glomerular epithelial cells to high glucose concentration results in modulation of high-affinity glucose transporters expression. Ren Fail 2007;29:353-358
21. Schiffer M, Susztak K, Ranalletta M, Raff AC, Böttinger EP, Charron MJ. Localization of the GLUT8 glucose transporter in murine kidney and regulation in vivo in nondiabetic and diabetic conditions. Am J Physiol Renal Physiol 2005;289:F186-F193
22. Lewko B, Bryl E, Witkowski JM, et al. Characterization of glucose uptake by cultured rat podocytes. Kidney Blood Press Res 2005;28:1-7
23. Wang Y, Heilig K, Saunders T, et al. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 2010;299:F99-F111
24. Buller CL, Heilig CW, Brosius FC 3rd. GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Am J Physiol Renal Physiol 2011;301:F588-F596
25. Zhang H, Schin M, Saha J, et al. Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2010;299: F91-F98
26. Abel ED, Kaulbach HC, Tian R, et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 1999;104:1703-1714
27. Moeller MJ, Sanden SK, Soofi A, Wiggins RC, Holzman LB. Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 2003;35:39-42
28. Atkins KB, Prezkop A, Park JL, et al. Preserved expression of GLUT4 prevents enhanced agonist-induced vascular reactivity and MYPT1 phosphorylation in hypertensive mouse aorta. Am J Physiol Heart Circ Physiol 2007;293:H402-H408
29. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-938
30. Zhang H, Saha J, Byun J, et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 2008;295:F1071-F1081
31. Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 2003;14:2484-2493
32. Fukuda A, Chowdhury MA, Venkatareddy MP, et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012;23:1351-1363
33. Lorne E, Zhao X, Zmijewski JW, et al. Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2-and 4-induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol 2009;41:237-245
34. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008;57:714-723
35. Peng F, Wu D, Gao B, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008;57:1683-1692
36. Liu L, Luo Y, Chen L, et al. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem 2010;285:38362-38373
37. Piguet AC, Semela D, Keogh A, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008;49:78-87
38. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011;16:30-38
39. Hallows KR, Mount PF, Pastor-Soler NM, Power DA. Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol 2010;298:F1067-F1077
40. Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 2010;40:323-332
41. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35
42. Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant 2009;24:3288-3296
43. Stuart CA, Howell ME, Baker JD, et al. Cycle training increased GLUT4 and activation of mammalian target of rapamycin in fast twitch muscle fibers. Med Sci Sports Exerc 2010;42:96-106
44. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005;16:2941-2952
45. Kim DK, Nam BY, Li JJ, et al. Translationally controlled tumour protein is associated with podocyte hypertrophy in a mouse model of type 1 diabetes. Diabetologia 2012;55:1205-1217
46. Shen WH, Chen Z, Shi S, et al. Cardiac restricted overexpression of kinasedead mammalian target of rapamycin (mTOR) mutant impairs the mTORmediated signaling and cardiac function. J Biol Chem 2008;283:13842-13849
47. Wiggins JE, Goyal M, Sanden SK, et al. Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 2005;16:2953-2966
48. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007;49:310-317
49. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72:1367-1373
50. Ohtomo S, Izuhara Y, Takizawa S, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007;72:1512-1519
51. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-6076
52. Kim JS, Kim IK, Lee SY, et al. The anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway. Cell Biol Int 2012;36:305-310
53. Lennon R, Welsh GI, Singh A, et al. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 2009;52:1944-1952
54. Kao AW, Noda Y, Johnson JH, Pessin JE, Saltiel AR. Aldolase mediates the association of F-actin with the insulin-responsive glucose transporter GLUT4. J Biol Chem 1999;274:17742-17747